Page last updated: 2024-12-11

a-317491

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

A-317491: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9829395
CHEMBL ID596234
SCHEMBL ID1160095
MeSH IDM0444786

Synonyms (41)

Synonym
NCGC00165956-01
5-[(3-phenoxyphenyl)methyl-[(1s)-tetralin-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid
a-317491
a317491
CHEMBL596234
bdbm86478
HY-15568
CS-1250 ,
475205-49-3
1,2,4-benzenetricarboxylic acid, 5-((((3-phenoxyphenyl)methyl)((1s)-1,2,3,4-tetrahydro-1-naphthalenyl)amino)carbonyl)-
s)-5-(((3-phenoxybenzyl)(1,2,3,4-tetrahydro-1-naphthalenyl)amino)carbonyl)-1,2,4-benzenetricarboxylic acid 5-(((3-phenoxybenzyl)((1s)-1,2,3,4-tetrahydro-1-naphthalenyl)amino)carbonyl)-1,2,4-benzenetricarboxylic acid
a 317491
unii-h327n08ipv
h327n08ipv ,
S8519
[3h]a 317491
gtpl4115
[3h]a-317491
gtpl5407
[3h]a317491
5-{[(3-phenoxyphenyl)methyl][(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl}benzene-1,2,4-tricarboxylic acid
SCHEMBL1160095
VQGBOYBIENNKMI-LJAQVGFWSA-N ,
5-({(3-phenoxybenzyl)[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl]amino}carbonyl)-1,2,4-benzenetricarboxylic acid
AC-33618
DTXSID40197185
AKOS030526820
5-((3-phenoxybenzyl)[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl]amino carbonyl)-1,2,4-benzenetricarboxylic acid
AS-57693
(s)-5-((3-phenoxybenzyl)(1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)benzene-1,2,4-tricarboxylic acid
antagonist a-317491
Q27074063
HMS3886B12
CCG-270075
a-317491 disodium salt
C75266
475205-49-3 (free acid)
A917529
5-[(3-phenoxyphenyl)methyl-[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid
abt 202abt 202
5-[[[(3-phenoxyphenyl)methyl][(1s)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]-1,2,4-benzenetricarboxylic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" dosing 3, 10 and 30 mg/kg."( A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats.
Ilyin, VI; Lee, G; Niosi, M; Nolan, S; Pearson, MS; Whiteside, GT; Wu, G, 2004
)
1.77
" Repeated morphine injections alone led to a significant rightward shift in the morphine dose-response curve compared with that with A-317491."( Blockade and reversal of spinal morphine tolerance by P2X3 receptor antagonist.
Jiang, W; Ma, X; Xu, H; Xu, T, 2015
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
DNA polymerase kappa isoform 1Homo sapiens (human)Potency16.83360.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2X purinoceptor 3Homo sapiens (human)IC50 (µMol)0.11100.00000.20301.5136AID1059222; AID1059226; AID1497295; AID1627253
P2X purinoceptor 3Homo sapiens (human)Ki0.00900.00900.04660.0891AID1627252
P2X purinoceptor 2Homo sapiens (human)Ki0.00900.00900.04660.0891AID1627252
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
response to hypoxiaP2X purinoceptor 3Homo sapiens (human)
signal transductionP2X purinoceptor 3Homo sapiens (human)
neuromuscular synaptic transmissionP2X purinoceptor 3Homo sapiens (human)
response to heatP2X purinoceptor 3Homo sapiens (human)
response to coldP2X purinoceptor 3Homo sapiens (human)
response to mechanical stimulusP2X purinoceptor 3Homo sapiens (human)
response to carbohydrateP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 3Homo sapiens (human)
urinary bladder smooth muscle contractionP2X purinoceptor 3Homo sapiens (human)
peristalsisP2X purinoceptor 3Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 3Homo sapiens (human)
regulation of synaptic plasticityP2X purinoceptor 3Homo sapiens (human)
behavioral response to painP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 3Homo sapiens (human)
sensory perception of tasteP2X purinoceptor 3Homo sapiens (human)
establishment of localization in cellP2X purinoceptor 3Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 3Homo sapiens (human)
protein homotrimerizationP2X purinoceptor 3Homo sapiens (human)
cellular response to ATPP2X purinoceptor 3Homo sapiens (human)
inorganic cation transmembrane transportP2X purinoceptor 3Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 3Homo sapiens (human)
response to hypoxiaP2X purinoceptor 2Homo sapiens (human)
response to ischemiaP2X purinoceptor 2Homo sapiens (human)
detection of hypoxic conditions in blood by carotid body chemoreceptor signalingP2X purinoceptor 2Homo sapiens (human)
neuromuscular synaptic transmissionP2X purinoceptor 2Homo sapiens (human)
neuromuscular junction developmentP2X purinoceptor 2Homo sapiens (human)
sensory perception of soundP2X purinoceptor 2Homo sapiens (human)
response to carbohydrateP2X purinoceptor 2Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 2Homo sapiens (human)
urinary bladder smooth muscle contractionP2X purinoceptor 2Homo sapiens (human)
peristalsisP2X purinoceptor 2Homo sapiens (human)
response to ATPP2X purinoceptor 2Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 2Homo sapiens (human)
behavioral response to painP2X purinoceptor 2Homo sapiens (human)
skeletal muscle fiber developmentP2X purinoceptor 2Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 2Homo sapiens (human)
sensory perception of tasteP2X purinoceptor 2Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 2Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
purinergic nucleotide receptor activityP2X purinoceptor 3Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 3Homo sapiens (human)
ATP bindingP2X purinoceptor 3Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 2Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 2Homo sapiens (human)
ATP bindingP2X purinoceptor 2Homo sapiens (human)
ligand-gated monoatomic ion channel activityP2X purinoceptor 2Homo sapiens (human)
identical protein bindingP2X purinoceptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneP2X purinoceptor 3Homo sapiens (human)
axonP2X purinoceptor 3Homo sapiens (human)
Schaffer collateral - CA1 synapseP2X purinoceptor 3Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseP2X purinoceptor 3Homo sapiens (human)
postsynapseP2X purinoceptor 3Homo sapiens (human)
receptor complexP2X purinoceptor 3Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
plasma membraneP2X purinoceptor 2Homo sapiens (human)
apical plasma membraneP2X purinoceptor 2Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 2Homo sapiens (human)
postsynapseP2X purinoceptor 2Homo sapiens (human)
neuronal dense core vesicleP2X purinoceptor 2Homo sapiens (human)
receptor complexP2X purinoceptor 2Homo sapiens (human)
plasma membraneP2X purinoceptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1059226Antagonist activity at recombinant human P2X3 receptor expressed in Xenopus oocytes assessed as inhibition of ATP-induced ion current preincubated for 20 mins followed by ATP addition by two-electrode voltage clamp assay2013European journal of medicinal chemistry, , Volume: 70Design and synthesis of potent and selective P2X₃ receptor antagonists derived from PPADS as potential pain modulators.
AID1627253Antagonist activity at human recombinant P2X3 receptor expressed in HEK293-Tet-on cells assessed as alpha,beta-methylene-ATP-stimulated Ca2+ influx by Fluo-4 assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds.
AID1627255Kinetic solubility of the compound in phosphate buffer at pH 7.4 by HPLC analysis2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds.
AID1059222Antagonist activity at recombinant human P2X3 receptor transfected in human 1321N1 cells assessed as inhibition of alpha, beta me-ATP-induced current by whole-cell patch-clamp method2013European journal of medicinal chemistry, , Volume: 70Design and synthesis of potent and selective P2X₃ receptor antagonists derived from PPADS as potential pain modulators.
AID453978Inhibition of HIV1 envelope gp41-mediated fusion of CHO cells expressing HIV1 envelope with calcein-AM labeled SupT1 cells by fluorescence assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
AID1627256Intrinsic clearance in human liver microsomes at 1 to 2.5 uM in presence of NADPH2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds.
AID1627252Antagonist activity at human P2X2/3 expressed in human1321N1 cells assessed as inhibition of alpha,beta-methylene-ATP-stimulated Ca2+ influx preincubated for 3 mins followed by alpha,beta-methylene-ATP addition measured after 3 mins by Fluo-4 assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
New P2X3 receptor antagonists. Part 1: Discovery and optimization of tricyclic compounds.
AID1497295Antagonist activity at human P2X3 receptor expressed in C6-BU-1 cells assessed as inhibition of calcium flux after 1 hr by Fluo-3AM dye based FLIPR assay2018Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: Initial structure-activity relationship studies of a hit from a high throughput screening.
AID1346621Human P2X3 (P2X receptors)2002Proceedings of the National Academy of Sciences of the United States of America, Dec-24, Volume: 99, Issue:26
A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's27 (45.76)29.6817
2010's28 (47.46)24.3611
2020's4 (6.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.00 (24.57)
Research Supply Index4.11 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]